Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb 15; 106(4):830-8.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cyclosporins
Dexamethasone
Disease Progression
Doxorubicin
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Multiple Myeloma
Survival Analysis
Treatment Outcome
Vincristine

authors with profiles

Richard A. Larson